login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SENTI BIOSCIENCES INC (SNTI) Stock News
USA
- NASDAQ:SNTI -
US81726A2096
-
Common Stock
1.98
USD
-0.07 (-3.41%)
Last: 10/22/2025, 5:43:11 PM
1.94
USD
-0.04 (-2.02%)
After Hours:
10/22/2025, 5:43:11 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SNTI Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Senti Biosciences, Inc.
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
8 days ago - By: Benzinga
- Mentions:
BCRX
XNCR
ADAP
SSKN
...
12 Health Care Stocks Moving In Tuesday's Intraday Session
16 days ago - By: Senti Biosciences, Inc.
Senti Bio to Present at BioJapan
a month ago - By: Senti Biosciences, Inc.
Senti Bio to Present at the MedInvest Biotech & Pharma Conference
2 months ago - By: Senti Biosciences, Inc.
Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2 months ago - By: Benzinga
- Mentions:
IBIO
SNGX
VKTX
PMCB
...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
2 months ago - By: Senti Biosciences, Inc.
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
2 months ago - By: Senti Biosciences, Inc.
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
3 months ago - By: Senti Biosciences, Inc.
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
3 months ago - By: Senti Biosciences, Inc.
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
3 months ago - By: Senti Biosciences, Inc.
Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
3 months ago - By: ACCESS Newswire
- Mentions:
AKTX
AMIX
CNSP
NVNO
...
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
3 months ago - By: Senti Biosciences, Inc.
Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum
3 months ago - By: Senti Biosciences, Inc.
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
4 months ago - By: Senti Biosciences, Inc.
Senti Bio Participates in Nasdaq Amplify Spotlight Series
4 months ago - By: Senti Biosciences, Inc.
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
4 months ago - By: Senti Biosciences, Inc.
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
5 months ago - By: Senti Biosciences, Inc.
Senti Biosciences Announces New Employment Inducement Grants
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
5 months ago - By: Senti Biosciences, Inc.
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
5 months ago - By: Senti Biosciences, Inc.
Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
5 months ago - By: Senti Biosciences, Inc.
Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
5 months ago - By: The Schall Law Firm
SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm
5 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
6 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
6 months ago - By: Senti Biosciences, Inc.
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
6 months ago - By: Senti Biosciences, Inc.
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development
6 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
6 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI
6 months ago - By: Senti Biosciences, Inc.
Senti Bio Releases Virtual Investor “What This Means” Segment
Please enable JavaScript to continue using this application.